Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 169 Cr.
- Current Price ₹ 103
- High / Low ₹ 153 / 68.6
- Stock P/E 11.3
- Book Value ₹ 59.1
- Dividend Yield 0.00 %
- ROCE 18.3 %
- ROE 16.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 86.4% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 116 days to 218 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | 112 | |
| 29 | 53 | 54 | 67 | 88 | 94 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 | 18 |
| OPM % | 4.7% | 11% | 13% | 19% | 15% | 16% |
| 0 | 0 | 0 | 0 | 4 | 2 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 | 18 |
| Tax % | 18% | 29% | 28% | 30% | 27% | 17% |
| 1 | 4 | 5 | 10 | 14 | 15 | |
| EPS in Rs | 8.45 | 8.37 | 9.07 | |||
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 22% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 86% |
| 3 Years: | 43% |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 23% |
| Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 66 | 80 |
| 3 | 3 | 4 | 5 | 30 | 8 | |
| 9 | 22 | 28 | 27 | 10 | 7 | |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 | 112 |
| 6 | 7 | 10 | 10 | 12 | 15 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | 1 |
| Investments | 0 | 0 | 0 | 7 | 52 | 16 |
| 12 | 27 | 37 | 44 | 58 | 80 | |
| Total Assets | 18 | 35 | 47 | 61 | 122 | 112 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | -11 | |
| -1 | -2 | -4 | -5 | -44 | 35 | |
| 0 | -0 | -0 | 2 | 67 | -24 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 | -0 |
| Free Cash Flow | -0 | 2 | 1 | 2 | -23 | -16 |
| CFO/OP | 103% | 57% | 72% | 46% | -120% | -33% |
Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 108 | 105 | 118 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 | 163 |
| Days Payable | 119 | 140 | 215 | 144 | 26 | 24 |
| Cash Conversion Cycle | 3 | 4 | 1 | 77 | 178 | 258 |
| Working Capital Days | 9 | 14 | 27 | 58 | 72 | 218 |
| ROCE % | 55% | 47% | 57% | 27% | 18% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Government Institution Revenue Share % |
|
||||
| Liquid Syrup Capacity Utilization % |
|||||
| Ointment Capacity Utilization % |
|||||
| ORS Powder Capacity Utilization % |
|||||
| Tablets Capacity Utilization % |
|||||
| Tablets Revenue INR Crore |
|||||
| Tablets Production Volume Million units |
|||||
| Total Licensed Formulations count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Filed Regulation 74(5) certificate for quarter ended September 30, 2026; shares fully in demat form.
-
Shareholders meeting
- Quest Laboratories' 28th AGM on 30 Sep 2026 approved all four resolutions.
-
Shareholders meeting
- Quest Laboratories held its 28th AGM on 30 September 2026; shareholders approved financials, auditor appointment and other resolutions.
-
Updates
- Quest Laboratories began strategic advisory collaboration with Niraga Capitals for growth, business development and capital initiatives.
-
Updates
- Phase-I expansion completed; Phase-II injection section construction done, with trial runs expected Jan-Feb 2027.
Annual reports
-
Annual Report 2026
from nse
-
Annual Report 2025
from nse
-
Annual Report 2024
from nse
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar